Skip to main content

Table 3 Percentages of participants reporting low levels of knowledge/skill by profession/specialty

From: Challenges associated with the integration of immuno-oncology agents in clinical practice

Knowledge or skill

Item

Profession/Specialty

Sig. a

Onco-logist

Rheuma-tologist

Emergency department physician

Pulmo-nologist

Patho-logist

Interventional radiologist

Clinical pharmacist

Physician assistant

Nurse practitioner

 

Knowledge

Safety profile of Avelumab

70.5%

(62)

90.5%

(38)

N/A

97.7%

(42)

N/A

N/A

82.2%

(74)

88.1%

(59)

72.9%

(62)

0.000

Safety profile of Alemtuzumab

64.4%

(56)

85.7%

(36)

N/A

95.2%

(40)

N/A

N/A

80.0%

(72)

86.6%

(58)

70.9%

(61)

0.000

Safety profile of Belimumab

79.3%

(69)

15.9%

(7)

N/A

95.3%

(41)

N/A

N/A

84.4%

(76)

88.1%

(59)

82.1%

(69)

0.000

Best practices for treatment of patients with lupus using immuno-oncology agents

79.8%

(63)

6.8%

(3)

N/A

N/A

N/A

97.4%

(38)

93.2%

(82)

83.1%

(54)

82.1%

(69)

0.000

Best practices for treatment of patients with rheumatoid arthritis or ankylosing spondylitis using immuno-oncology agents

76.9%

(60)

6.8%

(3)

N/A

N/A

N/A

87.5%

(35)

82%

(73)

83.1%

(54)

69.1%

(58)

0.000

Best practices for treatment of patients with psoriasis and/or psoriatic arthritis using immuno-oncology agents

71.8%

(56)

4.6%

(2)

N/A

N/A

N/A

89.7%

(35)

85.1%

(74)

82.8%

(53)

68.2%

(58)

0.000

Sources of information that can improve patients’ understanding of immuno-oncology agents

64.8%

(57)

65.9%

(29)

92.7%

(38)

73.2%

(30)

N/A

75%

(33)

75.3%

(67)

59.7%

(40)

43.9%

(38)

0.000

Sources of information that can mislead patients’ understanding of immuno-oncology agents

67%

(59)

75%

(33)

95.1%

(39)

80.5%

(33)

N/A

83.7%

(36)

80.9%

(72)

64.2%

(43)

56.8%

(50)

0.000

Skills

Explaining to patients the difference between immuno-oncology agents and chemotherapy

37.5%

(33)

45.2%

(19)

82.5%

(33)

N/A

N/A

57.1%

(24)

65.1%

(56)

33.3%

(22)

19.3%

(17)

0.000

Weighing the risks and benefits of treating patients with lupus with immuno-oncology agents

74.1%

(60)

6.8%

(3)

N/A

N/A

N/A

94.4%

(34)

89.5%

(77)

76.6%

(49)

76.5%

(62)

0.000

Identifying viable treatment options based on pharmacodiagnostic test reports

45.5%

(20)

N/A

N/A

73.7%

(28)

N/A

N/A

81%

(34)

60.5%

(26)

65.9%

(29)

0.008

Identifying markers that will characterize the progression of a specific type of cancer

41.9%

(18)

N/A

N/A

72.5%

(29)

46.5%

(20)

81.4%

(35)

76.2%

(32)

59.1%

(26)

54.5%

(24)

0.000

  1. N/A = Question was not asked to this profession/specialty sub-group 
  2. aSignificance across all profession/specialty sub-groups determined by two-sided Pearson’s chi-square tests
Back to article page

BMC Medical Education

ISSN: 1472-6920

Contact us